PRICING AND REIMBURSEMENT OF MEDICINES IN CENTRAL AND EAST EUROPEAN COUNTRIES
Mariela Marcheva, LublianaTosheva-Konteva, Guenka Petrova*
Medical University of Sofia, Faculty of Pharmacy, Bulgaria.
ABSTRACT
Each member state within EU 28 undertakes different actions when
shaping pharmaceutical policy. Especially over the past years during
the financial crisis governments face challenges of guaranteeing the
population best access to medicines within the slim budgets. The
Pharmaceutical Pricing and Reimbursement systems established by
Member States are usually quite complex. Each country uses different
schemes and policies, adapted to its own economic and health needs.
These national systems are regularly reviewed or adapted in order to
take account of political priorities, market evolutions and patients'
needs. The European Commission's initiatives in the field of pricing
and reimbursement therefore seek to foster cooperation through the
establishment of a structured dialogue between the competent national authorities and all
relevant stakeholders. The core objective is not only to enhance the functioning of the
Internal Market, but also to ensure that national systems achieve an adequate balance between
cost-containment, pharmaceutical innovation and patients' access to medicines.
Keywords: Pricing, Reimbursement, External Price Referencing, HTA, Europe.
[Download Article]
[Download Certifiate]